Low Price Pharma Stocks List – Pharma Penny Stocks India

The table below shows the Low Price Pharma Stocks List – Pharma Penny Stocks India based on the Highest Market Capitalization.

Best Low Price Pharma Stocks

The table below shows the Best Low Price Pharma Stocks based on 1 Year Return.

Low Price Pharma Stocks Nse

The table below shows Low Price Pharma Stocks Nse based on 1 Month Return.

Low Price Pharma Stocks

The table below shows Pharma Penny Stocks based on the Highest Daily Volume.

Low Price Pharma Stocks India

The table below shows Pharma Penny Stocks India based on the PE Ratio.

Low Price Pharma Stocks Under 10 Rs

The table below shows Pharma Penny Stocks Under 10 Rs.

Low Price Pharma Stocks List – FAQs

1. Which are the Best Pharma Stocks?

• Best Pharma Stocks #1: Piramal Pharma Ltd
• Best Pharma Stocks #2: Marksans Pharma Ltd
• Best Pharma Stocks #3: Sun Pharma Advanced Research Co Ltd
• Best Pharma Stocks #4: SeQuent Scientific Ltd
• Best Pharma Stocks #5: Suven Life Sciences Ltd

The stocks mentioned are ranked according to their one-year performance.

2. Is it good to invest in Pharma Penny Stocks?

Investing in pharmaceutical penny stocks carries a high risk due to volatility, limited liquidity, and uncertainty. It’s crucial to research thoroughly, consider your risk tolerance, and diversify your portfolio wisely.

3. What are the Low Price NSE Pharma Stocks?

Pharmaceutical stocks encompass companies researching, developing, manufacturing, and distributing drugs and healthcare products. A stock price below 50 Rs may be considered “low-priced” in this sector, but it’s essential to evaluate such stocks based on various factors before investing.

4. What is the future of Pharma Penny Stocks?

The future of Pharma Penny Stocks is uncertain and highly speculative, influenced by regulatory changes, drug developments, and market sentiment. Potential investors should exercise caution and conduct thorough research before investing.

Introduction to Low Price Pharma Stocks List

Low Price Pharma Stocks List – Highest Market Capitalization

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is ₹26,601.21 crore. The stock’s 1-month return is -13.22%, while its 1-year return is 58.75%. It is currently 52.83% away from its 52-week high.

Piramal Pharma Ltd is a leading pharmaceutical company engaged in contract development and manufacturing, complex generics, and consumer healthcare. The company has a strong global presence and provides high-quality pharmaceutical products and services. With a focus on innovation and R&D, Piramal Pharma continues to expand its offerings in speciality pharmaceuticals and healthcare solutions.

The company’s diverse portfolio includes APIs, drug formulations, and consumer healthcare products. With an emphasis on sustainable growth and strategic acquisitions, Piramal Pharma is continuously strengthening its market position. The company’s commitment to quality and regulatory compliance makes it a trusted partner in the global pharmaceutical industry.

Marksans Pharma Ltd

The Market Cap of Marksans Pharma Ltd is ₹9,388.19 crore. The stock’s 1-month return is -21.19%, while its 1-year return is 38.53%. It is currently 73.14% away from its 52-week high.

Marksans Pharma Ltd is a globally recognised pharmaceutical company specialising in the development, manufacturing, and marketing of generic pharmaceutical formulations. The company operates across multiple international markets, with a strong presence in regulated markets such as the US, UK, and Australia. Its product portfolio spans multiple therapeutic segments, including pain management, cardiovascular health, and gastrointestinal treatments.

Marksans Pharma focuses on innovation and strategic expansion to maintain its competitive edge. By leveraging advanced manufacturing capabilities and robust R&D investments, the company continues to develop cost-effective and high-quality pharmaceutical products. It aims to strengthen its position in the global pharmaceutical market through continued product launches and geographical expansion.

Sun Pharma Advanced Research Co Ltd

The Market Cap of Sun Pharma Advanced Research Co Ltd is ₹4,432.96 crore. The stock’s 1-month return is -21.43%, while its 1-year return is -64.97%. It is currently 246.12% away from its 52-week high.

Sun Pharma Advanced Research Company (SPARC) is a research-driven pharmaceutical entity focused on novel drug discovery and development. As an innovation arm of Sun Pharmaceutical Industries, SPARC is dedicated to developing cutting-edge pharmaceutical solutions, including new chemical entities (NCEs) and novel drug delivery systems (NDDS). The company’s R&D efforts primarily target oncology, neurology, ophthalmology, and dermatology.

Despite facing challenges in recent financial performance, SPARC continues to invest heavily in drug development and strategic partnerships. The company aims to deliver breakthrough therapies that address unmet medical needs and improve patient outcomes. With an emphasis on regulatory approvals and clinical advancements, SPARC remains committed to innovation in the global pharmaceutical industry.

Best Low Price Pharma Stocks – 1 Year Return

Shukra Pharmaceuticals Ltd
The Market Cap of Shukra Pharmaceuticals Ltd is ₹1,035.15 crore. The stock’s 1-month return is 9.81%, while its 1-year return is 169.16%. It is currently 14.85% away from its 52-week high.

Shukra Pharmaceuticals Ltd is a fast-growing pharmaceutical company that focuses on developing high-quality generic medicines. The company has gained recognition for its work in the areas of oncology, dermatology, and pain management treatments.

With a commitment to research and development, Shukra Pharmaceuticals strives to expand its portfolio of innovative drugs. The company’s strong performance has positioned it as a key player in the competitive pharmaceutical industry, offering effective solutions to improve patient health outcomes.

Jagsonpal Pharmaceuticals Ltd
The Market Cap of Jagsonpal Pharmaceuticals Ltd is ₹1,461.98 crore. The stock’s 1-month return is -21.58%, while its 1-year return is 81.55%. It is currently 48.96% away from its 52-week high.

Jagsonpal Pharmaceuticals Ltd is a leading player in the pharmaceutical industry, providing a wide range of products, including prescription medications, over-the-counter drugs, and medical devices. The company operates in various therapeutic areas, including ophthalmology, gynaecology, and orthopaedics.

With a strong commitment to patient health and well-being, Jagsonpal Pharmaceuticals focuses on offering high-quality, effective, and affordable medicines. The company is constantly expanding its reach in both domestic and international markets, ensuring its products are accessible to a wide range of patients.

Fermenta Biotech Ltd
The Market Cap of Fermenta Biotech Ltd is ₹822.74 crore. The stock’s 1-month return is -33.76%, while its 1-year return is 67.69%. It is currently 59.11% away from its 52-week high.

Fermenta Biotech Ltd is a biotechnology and pharmaceutical company with a focus on the development of high-quality API products. The company specialises in the production of enzymes, vitamins, and other biochemicals used in various therapeutic areas.

The company’s mission is to offer innovative solutions in the field of biotechnology, focusing on environmental sustainability and healthcare. Fermenta Biotech maintains high-quality manufacturing standards and strives to meet the evolving needs of patients across the world with cutting-edge biopharmaceutical solutions.

Low Price Pharma Stocks Nse – 1 Month Return

SeQuent Scientific Ltd
The Market Cap of SeQuent Scientific Ltd is ₹3,882.04 crore. The stock’s 1-month return is -5.03%, while its 1-year return is 24.73%. It is currently 54.94% away from its 52-week high.

SeQuent Scientific Ltd is a leading pharmaceutical company that specialises in the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves customers in both domestic and international markets, with a focus on animal health and human health sectors.

SeQuent has developed a strong portfolio of veterinary and human pharmaceutical products. With a commitment to innovation, the company aims to improve healthcare by providing high-quality, affordable medicines that address significant health challenges around the world.

Suven Life Sciences Ltd
The Market Cap of Suven Life Sciences Ltd is ₹2,749.26 crore. The stock’s 1-month return is -7.30%, while its 1-year return is 18.71%. It is currently 34.29% away from its 52-week high.

Suven Life Sciences Ltd is a research-driven pharmaceutical company focused on developing novel drug candidates. The company is primarily involved in contract research and manufacturing services, catering to global pharmaceutical clients with a focus on CNS (central nervous system) disorders and oncology.

The company strives to lead in drug discovery, leveraging its robust R&D capabilities. Suven Life Sciences is committed to finding breakthroughs that address the unmet medical needs of patients, offering innovative treatments for a range of complex diseases.

SMS Pharmaceuticals Ltd
The Market Cap of SMS Pharmaceuticals Ltd is ₹1,683.81 crore. The stock’s 1-month return is -8.73%, while its 1-year return is 11.19%. It is currently 100.09% away from its 52-week high.

SMS Pharmaceuticals Ltd is a pharmaceutical company that primarily focuses on the manufacturing and supply of high-quality active pharmaceutical ingredients (APIs) and intermediates. The company serves clients in multiple therapeutic areas, including antibiotics, anti-inflammatory, and cardiovascular drugs.

With a focus on innovation and quality, SMS Pharmaceuticals is committed to meeting the global pharmaceutical industry’s growing demand. The company has a strong manufacturing infrastructure and consistently works towards enhancing its product offerings to better serve its customers.

Pharma Penny Stocks – Highest Day Volume

Morepen Laboratories Ltd

The Market Cap of Morepen Laboratories Ltd is ₹2,722.23 crore. The stock’s 1-month return is -20.51%, while its 1-year return is 6.61%. It is currently 103.10% away from its 52-week high.

Morepen Laboratories Ltd is a well-established pharmaceutical company involved in the research, development, and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and diagnostic devices. The company has a strong presence in both domestic and international markets, catering to various segments, including over-the-counter (OTC) drugs and branded generics.

Despite a decline in its one-month return, the company’s stock has maintained relative stability over the past year. Morepen Laboratories Ltd continues to invest in research and development, with a focus on innovation and expansion. The company is also strengthening its diagnostic business and increasing its API production capabilities to sustain long-term growth.

Syncom Formulations (India) Ltd
The Market Cap of Syncom Formulations (India) Ltd is ₹1,608.34 crore. The stock’s 1-month return is -12.23%, while its 1-year return is 26.74%. It is currently 63.06% away from its 52-week high.

Syncom Formulations (India) Ltd is a pharmaceutical company that manufactures and markets high-quality generic drugs. The company specialises in producing finished dosage forms and APIs, catering to various global markets.

Syncom Formulations has a diverse product portfolio that includes medicines in therapeutic areas such as antibiotics, anti-inflammatory drugs, and central nervous system treatments. It focuses on providing affordable and accessible medicines to patients around the world while maintaining high-quality standards.

Nectar Lifesciences Ltd
The Market Cap of Nectar Lifesciences Ltd is ₹655.51 crore. The stock’s 1-month return is -23.54%, while its 1-year return is -18.24%. It is currently 93.29% away from its 52-week high.

Nectar Lifesciences Ltd is a pharmaceutical company focused on the manufacturing of high-quality APIs, formulations, and animal health products. The company operates in multiple therapeutic areas, including antibiotics, cardiovascular diseases, and pain management.

With a strong presence in both domestic and international markets, Nectar Lifesciences continues to grow its portfolio of affordable and effective pharmaceutical products. The company’s commitment to research and innovation drives its goal to offer better healthcare solutions worldwide.

Pharma Penny Stocks India – PE Ratio

Bliss GVS Pharma Ltd
The Market Cap of Bliss GVS Pharma Ltd is ₹1,315.34 crore. The stock’s 1-month return is -17.07%, while its 1-year return is 6.69%. It is currently 48.60% away from its 52-week high.

Bliss GVS Pharma Ltd is an innovative pharmaceutical company specialising in the development, manufacture, and sale of over-the-counter (OTC) products and generic medicines. The company has a wide product portfolio that includes pain relief, dermatology, and gastrointestinal drugs.

Bliss GVS Pharma is committed to providing affordable, high-quality medicines to its customers. The company has a strong presence in both the Indian and international markets, serving a broad base of consumers with its wide range of therapeutic products.

Wanbury Ltd
The Market Cap of Wanbury Ltd is ₹656.13 crore. The stock’s 1-month return is -17.65%, while its 1-year return is 30.31%. It is currently 61.59% away from its 52-week high.

Wanbury Ltd is a global pharmaceutical company specialising in manufacturing high-quality APIs and finished dosage forms. The company’s products span therapeutic segments such as cardiovascular, diabetes care, and antibiotics.

Wanbury Ltd aims to expand its footprint in both the domestic and international markets. With a strong focus on research and development, the company continuously works towards offering affordable, innovative, and high-quality healthcare solutions to address global medical challenges.

Anuh Pharma Ltd
The Market Cap of Anuh Pharma Ltd is ₹1,111.73 crore. The stock’s 1-month return is -21.28%, while its 1-year return is -26.99%. It is currently 59.16% away from its 52-week high.

Anuh Pharma Ltd is a pharmaceutical company with a focus on manufacturing and marketing active pharmaceutical ingredients (APIs). The company offers a wide range of products used in treating various diseases, including antifungal, antihistamine, and anti-inflammatory medicines.

Anuh Pharma operates with a strong emphasis on quality control and global standards. With a solid presence in key international markets, the company continues to expand its API portfolio while focusing on meeting the growing demand for high-quality, affordable pharmaceutical products worldwide.

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.